Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis

Current Opinion in Rheumatology

Volumn 26, Issue 5, 2014, Pages 562-569

  Weaver, Lehn K ^a   Behrens, Edward M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

cytokine storm; hemophagocytic lymphohistiocytosis; hemophagocytosis; macrophage activation syndrome

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; DEXAMETHASONE; ETOPOSIDE; GAMMA INTERFERON; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 6; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; MONOCLONAL ANTIBODY;

CELL MEDIATED CYTOTOXICITY; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; CYTOTOXIC T LYMPHOCYTE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EFFECTOR CELL; ERYTHROPHAGOCYTOSIS; GENE EXPRESSION PROFILING; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERINFLAMMATION; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MORBIDITY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SERODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MOUSE; PHAGOCYTOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MICE; PHAGOCYTOSIS;

EID: 84905503868     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000093     Document Type: Review

References (48)

1. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133-1138.
2. Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am 2012; 59:329-344.
3. Ohadi M, Lalloz MR, Sham P, et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet 1999; 64:165-171.
4. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957-1959.
5. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003; 115:461-473.
6. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11 Hum Mol Genet 2005; 14:827-834.
7. Cote M, Menager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest 2009; 119:3765-3773.
8. Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996; 382:262-265.
9. Menasche G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000; 25:173-176.
10. Clark RH, Stinchcombe JC, Day A, et al. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 2003; 4:1111-1120.
11. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2- domain encoding gene. Nat Genet 1998; 20:129-135.
12. Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006; 444:110-114.
13. Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBVassociated lymphoproliferation. J Clin Invest 2009; 119:1350-1358.
14. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol 2013; 161:609-622.
15. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106:561-566.
16. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124-131.
17. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146:598-604.
18. Lehmberg K, Pink I, Eulenburg C, et al. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 2013; 162:1245-1251.
19. Ho C, Yao X, Tian L, et al. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol 2014; 141:62-71.
20. Goel S, Polski JM, Imran H. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis. Ann Clin Lab Sci 2012; 42:21-25.
21. Gupta A, Tyrrell P, Valani R, et al. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 51:402-404.
22. Moore C Jr, Ormseth M, Fuchs H. Causes and significance of markedly elevated serum ferritin levels in an academic medical center. J Clin Rheumatol 2013; 19:324-328.
23. Sumegi J, Nestheide SV, Barnes MG, et al. Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis. Blood 2013; 121:e14-24.
24. Jessen B, Kogl T, Sepulveda FE, et al. Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice. Front Immunol 2013; 4:448.
25. Sepulveda FE, Debeurme F, Menasche G, et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood 2013; 121:595-603.
26. Jessen B, Bode SF, Ammann S, et al. The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type. Blood 2013; 121:2943-2951.
27. Hackmann Y, Graham SC, Ehl S, et al. Syntaxin binding mechanism and disease-causing mutations in Munc18-2. Proc Natl Acad Sci U S A 2013; 110:E4482-E4491.
28. Kogl T, Muller J, Jessen B, et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 2013; 121:604-613.
29. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011; 121:2264-2277.
30. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood 2013; 121:5184-5191.
31. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010; 49:1645-1653.
32. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013; 61:345-348.
33. Wada T, Kanegane H, Ohta K, et al. Sustained elevation of serum interleukin- 18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine 2014; 65:74-78.
34. Ohyagi H, Onai N, Sato T, et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity 2013; 39:584-598.
35. Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 2011; 208:1203-1214.
36. Billiau AD, Roskams T, Van Damme-Lombaerts R, et al. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 2005; 105:1648-1651.
37. Canna SW, Costa-Reis P, Bernal WE, et al. Alternative activation of lasercaptured murine hemophagocytes. Arthritis Rheumatol 2014. [Epub ahead of print]
38. Canna SW, Wrobel J, Chu N, et al. Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum 2013; 65:1764-1775.
39. Avau A, Mitera T, Put S, et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with complete Freund's adjuvant: regulation by IFN-gamma. Arthritis Rheumatol 2014; 66:1340-1351.
40. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014; 257:127-144.
41. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-1518.
42. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224ra25.
43. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013; 60:101-109.
44. Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr 2013; 163:1253-1259.
45. Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med 2014; 15:401-408.
46. Chi S, Ikezoe T, Takeuchi A, et al. Recombinant human soluble thrombomodulin is active against hemophagocytic lymphohistiocytosis associated with acquired immunodeficiency syndrome. Int J Hematol 2013; 98:615-619.
47. Yamamoto M, Hori T, Hatakeyama N, et al. Use of recombinant thrombomodulin in disseminated intravascular coagulation complicated hemophagocytic lymphohistiocytosis. Indian J Pediatr 2014; 81:288-291.
48. Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebocontrolled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41:2069-2079.